Lucerastat Shows Promise in Fabry Disease Trials
In a groundbreaking advancement in the treatment of Fabry disease, researchers have unveiled compelling results from a pivotal phase 3 clinical trial evaluating Lucerastat, a novel oral therapy designed to address...
Read moreDetails























